Christopher S. Coffey

5.2k total citations · 1 hit paper
55 papers, 2.7k citations indexed

About

Christopher S. Coffey is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, Christopher S. Coffey has authored 55 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Neurology. Recurrent topics in Christopher S. Coffey's work include Blood Pressure and Hypertension Studies (7 papers), Parkinson's Disease Mechanisms and Treatments (5 papers) and Prostate Cancer Diagnosis and Treatment (5 papers). Christopher S. Coffey is often cited by papers focused on Blood Pressure and Hypertension Studies (7 papers), Parkinson's Disease Mechanisms and Treatments (5 papers) and Prostate Cancer Diagnosis and Treatment (5 papers). Christopher S. Coffey collaborates with scholars based in United States, Canada and Netherlands. Christopher S. Coffey's co-authors include Raymond L. Benza, C. Gregory Elliott, Michael D. McGoon, Theodore G. Liou, David B. Badesch, Adaani Frost, Aimee J. Foreman, Robert P. Frantz, Robyn J. Barst and Mardi Gomberg‐Maitland and has published in prestigious journals such as Circulation, PLoS ONE and Neurology.

In The Last Decade

Christopher S. Coffey

53 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Predicting Survival in Pulmonary Arterial Hypertension

2010 1.1k citations Raymond L. Benza, Dave P. Miller et al. Circulation profile →

Peers

Countries citing papers authored by Christopher S. Coffey

Since Specialization

Citations

This map shows the geographic impact of Christopher S. Coffey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher S. Coffey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher S. Coffey more than expected).

Fields of papers citing papers by Christopher S. Coffey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher S. Coffey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher S. Coffey. The network helps show where Christopher S. Coffey may publish in the future.

Co-authorship network of co-authors of Christopher S. Coffey

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher S. Coffey. A scholar is included among the top collaborators of Christopher S. Coffey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher S. Coffey. Christopher S. Coffey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts 2023 ·npj Parkinson s Disease ·Kalpana Merchant, Tanya Simuni, (unknown), Chelsea Caspell‐Garcia, Michael C. Brumm, Kelly Nudelman, (unknown), F. Hsieh, Roy N. Alcalay, Christopher S. Coffey, Lana M. Chahine, Tatiana Foroud, Andrew Singleton, Daniel Weintraub, Samantha J. Hutten, Todd Sherer, Brit Mollenhauer, Andrew Siderowf, Caroline M. Tanner, Kenneth Marek, (unknown)	12
2	Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease 2021 ·Parkinsonism & Related Disorders ·Alberto J. Espay, David-Erick Lafontant, Kathleen L. Poston, Chelsea Caspell‐Garcia, Luca Marsili, (unknown), (unknown), (unknown), Christopher S. Coffey, Abhimanyu Mahajan, Kariem Ezzat, Andrea Sturchio	9
3	Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) 2018 ·Journal of Parkinson s Disease ·Lana M. Chahine, Thomas G. Beach, (unknown), Chelsea Caspell‐Garcia, Christopher S. Coffey, Michael C. Brumm, Charles H. Adler, Geidy E. Serrano, Carly Linder, Sherri Mosovsky, Tatiana Foroud, (unknown), Dixie Ecklund, John Seibyl, Danna Jennings, Vanessa Arnedo, Lindsey Riley, Kuldip D. Dave, Brit Mollenhauer, (unknown)	15
4	Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension 2016 ·Journal of the American Society of Hypertension ·Steven M. Smith, Nicholas W. Carris, Eric Dietrich, John G. Gums, Liz Uribe, Christopher S. Coffey, Tyler H. Gums, Barry L. Carter	26
5	Ethical Considerations in Adaptive Design Clinical Trials 2016 ·Therapeutic Innovation & Regulatory Science ·(unknown), John W. Loewy, Sandeep Menon, (unknown), Erik Pulkstenis, (unknown), Christopher S. Coffey	12
6	NN 102/SPRINT-MS Phase II Trial of Ibudilast in Progressive MS: Baseline Characteristics (P7.214) 2015 ·Neurology ·Robert J. Fox, Christopher S. Coffey, Merit Cudkowicz, (unknown), Andrew Goodman, Eric C. Klawiter, Kazuko Matsuda, Michelle McGovern, Elizabeth McNeil, Robert T. Naismith, Jon Yankey	1
7	The NIHSS Supplementary Motor Scale: A Valid Tool for Multidisciplinary Recovery Trials 2013 ·Cerebrovascular Diseases ·Enrique C. Leira, Christopher S. Coffey, Ricardo E. Jorge, Susanne M. Morton, Michael T. Froehler, Patricia H. Davis, Harold P. Adams	3
8	Clinical Features and Racial/Ethnic Differences Among the 3020 Participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial 2012 ·Journal of Stroke and Cerebrovascular Diseases ·Carole L. White, Jeff M. Szychowski, Ana Roldan, (unknown), E. Javier Pretell, Óscar H. Del Brutto, Carlos S. Kase, Antonio Araúz, Brett C. Meyer, Irene Meissner, Bart M. Demaerschalk, Leslie A. McClure, Christopher S. Coffey, Lesly A. Pearce, Robin Conwit, (unknown), Kalyani Peri, Pablo E. Pérgola, Robert G. Hart, Oscar Benavente	24
9	Sample size re-estimation in an on-going NIH-sponsored clinical trial: The secondary prevention of small subcortical strokes experience 2012 ·Contemporary Clinical Trials ·Leslie A. McClure, Jeff M. Szychowski, Oscar Benavente, Christopher S. Coffey	4
10	Adaptive trial designs: a review of barriers and opportunities 2012 ·Trials ·John A. Kairalla, Christopher S. Coffey, (unknown), Keith E. Muller	116
11	Predicting Survival in Pulmonary Arterial Hypertension breakdown → 2010 ·Circulation ·Raymond L. Benza, Dave P. Miller, Mardi Gomberg‐Maitland, Robert P. Frantz, Aimee J. Foreman, Christopher S. Coffey, Adaani Frost, Robyn J. Barst, David B. Badesch, C. Gregory Elliott, Theodore G. Liou, Michael D. McGoon	1139
12	Cardiovascular Risk Associated with Interactions among Polymorphisms in Genes from the Renin-Angiotensin, Bradykinin, and Fibrinolytic Systems 2010 ·PLoS ONE ·John P. Bentley, Folkert W. Asselbergs, Christopher S. Coffey, Patricia R. Hebert, Jason H. Moore, Hans L. Hillege, Wiek H. van Gilst	11
13	Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels 2007 ·Genomics ·Folkert W. Asselbergs, Scott M. Williams, Patricia R. Hebert, Christopher S. Coffey, Hans L. Hillege, Gerjan Navis, Douglas E. Vaughan, Wiek H. van Gilst, Jason H. Moore	24
14	Genetic programming neural networks: A powerful bioinformatics tool for human genetics 2006 ·Applied Soft Computing ·Marylyn D. Ritchie, Alison A. Motsinger‐Reif, William S. Bush, Christopher S. Coffey, Jason H. Moore	47
15	Assessment of Real-Time 3D Visualization for Cardiothoracic Diagnostic Evaluation and Surgery Planning 2005 ·Journal of Digital Imaging ·Bradley M. Hemminger, Paul L. Molina, Thomas M. Egan, Frank C. Detterbeck, Keith E. Muller, Christopher S. Coffey, Joseph K. T. Lee	24
16	Reporting of model validation procedures in human studies of genetic interactions 2003 ·Nutrition ·Christopher S. Coffey, Patricia R. Hebert, Harlan M. Krumholz, Thomas M. Morgan, Scott M. Williams, Jason H. Moore	22
17	Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. 2003 ·Journal of Hypertension ·Raed Aqel, Gilbert J. Zoghbi, (unknown), (unknown), David A. Calhoun, Christopher S. Coffey, Gilbert J. Perry, Ami E. Iskandrian	61
18	The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA 2002 ·Urologic Oncology Seminars and Original Investigations ·(unknown), Joseph A. Smith, Scott B. Shappell, Christopher S. Coffey, Sam S. Chang, Michael S. Cookson	31
19	Winter Viruses 2002 ·Archives of Internal Medicine ·Marie R. Griffin, Christopher S. Coffey, Kathleen M. Neuzil, Edward F. Mitchel, Peter F. Wright, Kathryn M. Edwards	90
20	Comparison of computer workstation with light box for detecting setup errors from portal images 1999 ·International Journal of Radiation OncologyBiologyPhysics ·Aziz A. Boxwala, Edward L. Chaney, Daniel Fritsch, (unknown), Christopher S. Coffey, (unknown), Keith E. Muller	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact